{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T21:12:43Z","timestamp":1791407563093,"version":"4.3.3"},"reference-count":198,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Controlled Release"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.jconrel.2023.09.040","type":"journal-article","created":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T05:49:20Z","timestamp":1696139360000},"page":"415-434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery"],"prefix":"10.1016","volume":"363","author":[{"given":"In\u00eas","family":"Domingues","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle A.","family":"Leclercq","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Beloqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jconrel.2023.09.040_bb0005","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","article-title":"EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease","volume":"64","author":"L. European Association for the Study of the","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0010","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0015","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1111\/jgh.13857","article-title":"Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 1: definition, risk factors and assessment","volume":"33","author":"Wong","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0020","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2021-326874","article-title":"Current therapies and new developments in NASH","volume":"71","author":"Dufour","year":"2022","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0025","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0030","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the Most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0035","series-title":"Non-Alcoholic Fatty Liver Disease: A Practical Guide","first-page":"46","article-title":"Emerging concepts on the pathogenesis of non-alcoholic steatohepatitis (NASH)","author":"Leclercq","year":"2013"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0040","doi-asserted-by":"crossref","first-page":"2041","DOI":"10.1111\/jgh.15156","article-title":"Global epidemiology of lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"35","author":"Lu","year":"2020","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0045","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1111\/jgh.13856","article-title":"The Asia-Pacific working party on non-alcoholic fatty liver disease guidelines 2017-part 2: management and special groups","volume":"33","author":"Chitturi","year":"2018","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0050","article-title":"A multi-society Delphi consensus statement on new fatty liver disease nomenclature, Hepatology","author":"Rinella","year":"2023","journal-title":"Newsome, N.N.c., group."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0055","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","article-title":"Steatohepatitis: a tale of two \u201chits\u201d?","volume":"114","author":"Day","year":"1998","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0060","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.metabol.2015.12.012","article-title":"The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD)","volume":"65","author":"Buzzetti","year":"2016","journal-title":"Metabolism"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0065","doi-asserted-by":"crossref","DOI":"10.1016\/j.endmts.2021.100089","article-title":"The global epidemiology of nonalcoholic steatohepatitis (NASH) and associated risk factors\u2013A targeted literature review","volume":"3","author":"Dufour","year":"2021","journal-title":"Endocrine and Metabolic Science"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0070","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1172\/JCI23621","article-title":"Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease","volume":"115","author":"Donnelly","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0075","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1172\/JCI134165","article-title":"Insulin resistance drives hepatic de novo lipogenesis in nonalcoholic fatty liver disease","volume":"130","author":"Smith","year":"2020","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0080","doi-asserted-by":"crossref","first-page":"489","DOI":"10.2337\/dc20-1644","article-title":"Hepatic insulin resistance is not pathway selective in humans with nonalcoholic fatty liver disease","volume":"44","author":"Ter Horst","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0085","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/s41591-018-0104-9","article-title":"Mechanisms of NAFLD development and therapeutic strategies","volume":"24","author":"Friedman","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0090","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00535-013-0758-5","article-title":"Mechanisms of hepatic triglyceride accumulation in non-alcoholic fatty liver disease","volume":"48","author":"Kawano","year":"2013","journal-title":"J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0095","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.jhep.2021.11.009","article-title":"A new perspective on NAFLD: focusing on lipid droplets","volume":"76","author":"Scorletti","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0100","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/s41419-020-03003-w","article-title":"Understanding lipotoxicity in NAFLD pathogenesis: is CD36 a key driver?","volume":"11","author":"Rada","year":"2020","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0105","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.cmet.2010.04.005","article-title":"Defective hepatic autophagy in obesity promotes ER stress and causes insulin resistance","volume":"11","author":"Yang","year":"2010","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0110","doi-asserted-by":"crossref","first-page":"12093","DOI":"10.1074\/jbc.M510660200","article-title":"Free fatty acids induce JNK-dependent hepatocyte lipoapoptosis","volume":"281","author":"Malhi","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0115","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1016\/j.jhep.2014.07.024","article-title":"Hepatocyte free cholesterol lipotoxicity results from JNK1-mediated mitochondrial injury and is HMGB1 and TLR4-dependent","volume":"61","author":"Gan","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0120","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1007\/s00109-014-1170-1","article-title":"NLRP3 inflammasome activation is required for fibrosis development in NAFLD","volume":"92","author":"Wree","year":"2014","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0125","doi-asserted-by":"crossref","first-page":"742382","DOI":"10.3389\/fcvm.2021.742382","article-title":"Non-alcoholic steatohepatitis pathogenesis, diagnosis, and treatment","volume":"8","author":"Zhu","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0130","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1097\/TP.0000000000002480","article-title":"Nonalcoholic fatty liver disease: basic Pathogenetic mechanisms in the progression from NAFLD to NASH","volume":"103","author":"Pierantonelli","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0135","doi-asserted-by":"crossref","DOI":"10.1172\/JCI143690","article-title":"Lipid-induced endothelial vascular cell adhesion molecule 1 promotes nonalcoholic steatohepatitis pathogenesis","volume":"131","author":"Furuta","year":"2021","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0140","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1038\/s41467-023-36776-7","article-title":"Molecular imaging of liver inflammation using an anti-VCAM-1 nanobody","volume":"14","author":"Nachit","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0145","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1002\/hep.25539","article-title":"Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease","volume":"55","author":"Lomonaco","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0150","doi-asserted-by":"crossref","first-page":"14859","DOI":"10.1038\/ncomms14859","article-title":"Pharmacological inhibition of adipose triglyceride lipase corrects high-fat diet-induced insulin resistance and hepatosteatosis in mice","volume":"8","author":"Schweiger","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0155","doi-asserted-by":"crossref","DOI":"10.3390\/metabo11030155","article-title":"Insulin resistance across the spectrum of nonalcoholic fatty liver disease","volume":"11","author":"Armandi","year":"2021","journal-title":"Metabolites"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple parallel hits hypothesis in nonalcoholic fatty liver disease: revisited after a decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0165","doi-asserted-by":"crossref","DOI":"10.1053\/j.gastro.2015.05.044","article-title":"Association of adipose tissue inflammation with histologic severity of nonalcoholic fatty liver disease","volume":"149","author":"du Plessis","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0170","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1053\/j.gastro.2020.01.049","article-title":"Nonalcoholic fatty liver disease: modulating gut microbiota to improve severity?","volume":"158","author":"Aron-Wisnewsky","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0175","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/j.dsx.2020.09.026","article-title":"Pathophysiological mechanisms underlying MAFLD","volume":"14","author":"Kuchay","year":"2020","journal-title":"Diabetes Metab. Syndr."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0180","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.jhep.2017.11.014","article-title":"Lipotoxicity and the gut-liver axis in NASH pathogenesis","volume":"68","author":"Marra","year":"2018","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0185","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1038\/nm.3282","article-title":"Targeting of alphav integrin identifies a core molecular pathway that regulates fibrosis in several organs","volume":"19","author":"Henderson","year":"2013","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0190","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0195","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3389\/fcell.2018.00150","article-title":"Role of metabolism in hepatic stellate cell activation and Fibrogenesis","volume":"6","author":"Hou","year":"2018","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0200","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/path.2888","article-title":"Increased production of sonic hedgehog by ballooned hepatocytes","volume":"224","author":"Rangwala","year":"2011","journal-title":"J. Pathol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0205","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1016\/j.clnu.2022.06.037","article-title":"The effectiveness and acceptability of Mediterranean diet and calorie restriction in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis","volume":"41","author":"Haigh","year":"2022","journal-title":"Clin. Nutr."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0210","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jhep.2019.04.013","article-title":"The beneficial effects of Mediterranean diet over low-fat diet may be mediated by decreasing hepatic fat content","volume":"71","author":"Gepner","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0215","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2018.01.005","article-title":"An integrated understanding of the rapid metabolic benefits of a carbohydrate-restricted diet on hepatic steatosis in humans","volume":"27","author":"Mardinoglu","year":"2018","journal-title":"Cell Metab"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0220","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1136\/gutjnl-2020-323106","article-title":"Effect of green-Mediterranean diet on intrahepatic fat: the DIRECT PLUS randomised controlled trial","volume":"70","author":"Yaskolka Meir","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0225","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1136\/gut.2011.242073","article-title":"Resistance exercise reduces liver fat and its mediators in non-alcoholic fatty liver disease independent of weight loss","volume":"60","author":"Hallsworth","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0230","doi-asserted-by":"crossref","first-page":"6485","DOI":"10.1038\/s41598-022-10481-9","article-title":"Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool","volume":"12","author":"Babu","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0235","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12944-018-0852-z","article-title":"Exercise without dietary changes alleviates nonalcoholic fatty liver disease without weight loss benefits","volume":"17","author":"Ok","year":"2018","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0240","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1001\/jamainternmed.2016.3202","article-title":"Effects of moderate and vigorous exercise on nonalcoholic fatty liver disease: a randomized clinical trial","volume":"176","author":"Zhang","year":"2016","journal-title":"JAMA Intern. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0245","doi-asserted-by":"crossref","first-page":"734859","DOI":"10.3389\/fnut.2021.734859","article-title":"NAFLD and physical exercise: ready, steady, go!","volume":"8","author":"Cigrovski Berkovic","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0250","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/j.clnu.2022.08.001","article-title":"Statins\u2019 efficacy in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"41","author":"Boutari","year":"2022","journal-title":"Clin. Nutr."},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.040_bb0255","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1097\/HEP.0000000000000323","article-title":"AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease","volume":"77","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"issue":"23","key":"10.1016\/j.jconrel.2023.09.040_bb0260","first-page":"04980-2","article-title":"Treating NASH by targeting peroxisome proliferator-activated receptors","volume":"S0168-8278","author":"Staels","year":"2023","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0265","doi-asserted-by":"crossref","first-page":"113888","DOI":"10.1016\/j.addr.2021.113888","article-title":"Therapeutic targets, novel drugs, and delivery systems for diabetes associated NAFLD and liver fibrosis","volume":"176","author":"Kumar","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0270","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/s41575-020-00366-5","article-title":"Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors","volume":"18","author":"Francque","year":"2021","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0275","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1136\/gutjnl-2015-310798","article-title":"Liver PPARalpha is crucial for whole-body fatty acid homeostasis and is protective against NAFLD","volume":"65","author":"Montagner","year":"2016","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0280","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1074\/jbc.M110.138115","article-title":"Role of peroxisome proliferator-activated receptor delta\/beta in hepatic metabolic regulation","volume":"286","author":"Liu","year":"2011","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0285","doi-asserted-by":"crossref","first-page":"473","DOI":"10.3389\/fendo.2018.00473","article-title":"Deciphering the roles of PPARgamma in adipocytes via dynamic change of transcription complex","volume":"9","author":"Ma","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0290","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa2036205","article-title":"A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH","volume":"385","author":"Francque","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0295","doi-asserted-by":"crossref","first-page":"109609","DOI":"10.1016\/j.biopha.2019.109609","article-title":"Role of farnesoid X receptor in hepatic steatosis in nonalcoholic fatty liver disease","volume":"121","author":"Xi","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0300","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.clinthera.2021.01.021","article-title":"Therapy for nonalcoholic fatty liver disease: current options and future directions","volume":"43","author":"Campbell","year":"2021","journal-title":"Clin Ther"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0305","doi-asserted-by":"crossref","first-page":"105803","DOI":"10.1016\/j.cct.2019.06.017","article-title":"REGENERATE: design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis","volume":"84","author":"Ratziu","year":"2019","journal-title":"Contemp. Clin. Trials"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0310","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0315","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.jhep.2021.10.018","article-title":"EDP-305 in patients with NASH: a phase II double-blind placebo-controlled dose-ranging study","volume":"76","author":"Ratziu","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0320","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S2468-1253(19)30184-0","article-title":"Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial","volume":"4","author":"Traussnigg","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0325","doi-asserted-by":"crossref","first-page":"5503","DOI":"10.1038\/s41467-021-25701-5","article-title":"A phase 2, proof of concept, randomised controlled trial of berberine ursodeoxycholate in patients with presumed non-alcoholic steatohepatitis and type 2 diabetes","volume":"12","author":"Harrison","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0330","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.cmet.2023.01.006","article-title":"The role of hepatokines in NAFLD","volume":"35","author":"Stefan","year":"2023","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0335","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1038\/nrd.2015.9","article-title":"Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23","volume":"15","author":"Degirolamo","year":"2016","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0340","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1172\/JCI23606","article-title":"FGF-21 as a novel metabolic regulator","volume":"115","author":"Kharitonenkov","year":"2005","journal-title":"J. Clin. Invest."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0345","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.1006962107","article-title":"Fibroblast growth factor 21 regulates energy metabolism by activating the AMPK-SIRT1-PGC-1alpha pathway","volume":"107","author":"Chau","year":"2010","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0350","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/s41591-021-01425-3","article-title":"Efruxifermin in non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a trial","volume":"27","author":"Harrison","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0355","volume":"5","author":"Frias","year":"2021","journal-title":"Journal Endocrine Society"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0360","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fmed.2020.00331","article-title":"Selective thyroid hormone receptor-Beta (TRbeta) agonists: new perspectives for the treatment of metabolic and neurodegenerative disorders","volume":"7","author":"Saponaro","year":"2020","journal-title":"Front Med (Lausanne)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0365","doi-asserted-by":"crossref","DOI":"10.1177\/20420188211034300","article-title":"Therapeutic approaches for non-alcoholic steatohepatitis","volume":"12","author":"Van Gaal","year":"2021","journal-title":"Ther. Adv. Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0370","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1016\/S0140-6736(19)32517-6","article-title":"Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial","volume":"394","author":"Harrison","year":"2019","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.jconrel.2023.09.040_bb0375","doi-asserted-by":"crossref","first-page":"3284","DOI":"10.1021\/acs.jmedchem.2c01669","article-title":"Discovery of highly potent and selective thyroid hormone receptor beta agonists for the treatment of nonalcoholic steatohepatitis","volume":"66","author":"Hu","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0380","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1007\/s00125-021-05442-2","article-title":"Liver-targeting drugs and their effect on blood glucose and hepatic lipids","volume":"64","author":"Gastaldelli","year":"2021","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0385","doi-asserted-by":"crossref","first-page":"15661","DOI":"10.1038\/s41598-022-19459-z","article-title":"FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models","volume":"12","author":"O\u2019Farrell","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0390","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1053\/j.gastro.2021.07.025","article-title":"TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial","volume":"161","author":"Loomba","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0395","doi-asserted-by":"crossref","first-page":"2952","DOI":"10.1111\/jgh.15580","article-title":"The effects of dapagliflozin on hepatic and visceral fat in type 2 diabetes patients with non-alcoholic fatty liver disease","volume":"36","author":"Phrueksotsai","year":"2021","journal-title":"J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0400","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cmet.2018.03.001","article-title":"Mechanisms of action and therapeutic application of glucagon-like Peptide-1","volume":"27","author":"Drucker","year":"2018","journal-title":"Cell Metab."},{"issue":"1","key":"10.1016\/j.jconrel.2023.09.040_bb0405","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1210\/endrev\/bnac018","article-title":"Glucagon-like peptide-1 receptor-based therapeutics for metabolic liver disease","volume":"44","author":"Yabut","year":"2022","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0410","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.phrs.2018.09.025","article-title":"Multiple target tissue effects of GLP-1 analogues on non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH)","volume":"137","author":"Bifari","year":"2018","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0415","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0140-6736(15)00803-X","article-title":"Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study","volume":"387","author":"Armstrong","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0420","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","article-title":"A placebo-controlled trial of subcutaneous Semaglutide in nonalcoholic steatohepatitis","volume":"384","author":"Newsome","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0425","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.2337\/dc20-2151","article-title":"Effects of Cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study","volume":"44","author":"Nahra","year":"2021","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0430","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27134315","article-title":"Tirzepatide, a new era of dual-targeted treatment for diabetes and obesity: a mini-review","volume":"27","author":"Chavda","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0435","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.2337\/dc19-1892","article-title":"Effects of novel dual GIP and GLP-1 receptor agonist Tirzepatide on biomarkers of nonalcoholic steatohepatitis in patients with type 2 diabetes","volume":"43","author":"Hartman","year":"2020","journal-title":"Diabetes Care"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0440","doi-asserted-by":"crossref","first-page":"100051","DOI":"10.1016\/j.crphar.2021.100051","article-title":"ATP citrate lyase inhibitor Bempedoic acid alleviate long term HFD induced NASH through improvement in glycemic control, reduction of hepatic triglycerides & total cholesterol, modulation of inflammatory & fibrotic genes and improvement in NAS score","volume":"2","author":"Sanjay","year":"2021","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0445","doi-asserted-by":"crossref","first-page":"1028355","DOI":"10.3389\/fcvm.2022.1028355","article-title":"Mechanism of action and therapeutic use of bempedoic acid in atherosclerosis and metabolic syndrome","volume":"9","author":"Biolo","year":"2022","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0450","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.cmet.2022.05.004","article-title":"Inhibition of ATP-citrate lyase improves NASH, liver fibrosis, and dyslipidemia","volume":"34","author":"Morrow","year":"2022","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0455","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/hep4.1453","article-title":"Icosabutate exerts beneficial effects upon insulin sensitivity, hepatic inflammation, lipotoxicity, and fibrosis in mice","volume":"4","author":"van den Hoek","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0460","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jhep.2021.12.004","article-title":"A structurally engineered fatty acid, icosabutate, suppresses liver inflammation and fibrosis in NASH","volume":"76","author":"Fraser","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0465","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1111\/liv.14643","article-title":"Dual targeting of hepatic fibrosis and atherogenesis by icosabutate, an engineered eicosapentaenoic acid derivative","volume":"40","author":"Stokman","year":"2020","journal-title":"Liver Int."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0470","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.cell.2010.07.041","article-title":"GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects","volume":"142","author":"Oh","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0475","doi-asserted-by":"crossref","first-page":"7806860","DOI":"10.1155\/2020\/7806860","article-title":"Aspirin improves nonalcoholic fatty liver disease and atherosclerosis through regulation of the PPARdelta-AMPK-PGC-1alpha pathway in Dyslipidemic conditions","volume":"2020","author":"Han","year":"2020","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0480","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1016\/j.cgh.2019.04.061","article-title":"Daily aspirin use associated with reduced risk for fibrosis progression in patients with nonalcoholic fatty liver disease","volume":"17","author":"Simon","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0485","doi-asserted-by":"crossref","first-page":"569","DOI":"10.3748\/wjg.v20.i2.569","article-title":"Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis","volume":"20","author":"Du","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0490","first-page":"8644","article-title":"Pentoxifylline and its association with kaempferol improve NASH-associated manifestation in mice through anti-apoptotic, anti-necroptotic, antioxidant, and anti-inflammatory mechanisms","volume":"26","author":"Hamouda","year":"2022","journal-title":"European Review for Medical and Pharmacological Sciences"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0495","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1111\/apt.16664","article-title":"Randomised clinical trial: a phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis","volume":"54","author":"Safadi","year":"2021","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0500","series-title":"Obesity, Fatty Liver and Liver Cancer","article-title":"Chemokines and chemokine receptors in the development of NAFLD","author":"Yoon-Seok Roh","year":"2018"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0505","series-title":"Clinical Info HIV.gov, Drug Database","author":"Leronlimab","year":"2022"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0510","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1002\/hep.32181","article-title":"BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial","volume":"75","author":"Lawitz","year":"2022","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0515","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/nbt1396","article-title":"Resolution of liver cirrhosis using vitamin A-coupled liposomes to deliver siRNA against a collagen-specific chaperone","volume":"26","author":"Sato","year":"2008","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0520","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00733-2020","article-title":"Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models","volume":"7","author":"Liu","year":"2021","journal-title":"ERJ Open Res"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0525","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1080\/13543784.2020.1703948","article-title":"Cyclophilin inhibition as a potential treatment for nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Ure","year":"2020","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0530","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1002\/hep4.2100","article-title":"Rencofilstat, a cyclophilin inhibitor: a phase 2a, multicenter, single-blind, placebo-controlled study in F2\/F3 NASH","volume":"6","author":"Harrison","year":"2022","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0535","doi-asserted-by":"crossref","first-page":"101628","DOI":"10.1016\/j.isci.2020.101628","article-title":"Endogenous metabolic modulators: emerging therapeutic potential of amino acids","volume":"23","author":"Hamill","year":"2020","journal-title":"iScience"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0540","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.14309\/ajg.0000000000001375","article-title":"Safety, tolerability, and biologic activity of AXA1125 and AXA1957 in subjects with nonalcoholic fatty liver disease","volume":"116","author":"Harrison","year":"2021","journal-title":"Am. J. Gastroenterol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0545","doi-asserted-by":"crossref","first-page":"14960","DOI":"10.1080\/21655979.2023.2185941","article-title":"The clinical effect of probiotics on patients with non-alcoholic fatty liver disease: a meta-analysis","volume":"13","author":"Wang","year":"2022","journal-title":"Bioengineered"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0550","doi-asserted-by":"crossref","first-page":"1155306","DOI":"10.3389\/fnut.2023.1155306","article-title":"Effects of probiotics on non-alcoholic fatty liver disease: a review of human clinical trials","volume":"10","author":"Cao","year":"2023","journal-title":"Front. Nutr."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0555","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jhep.2022.04.003","article-title":"Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: a randomised, open-label phase II trial","volume":"77","author":"Alkhouri","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0560","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1038\/s41591-022-01861-9","article-title":"Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study","volume":"28","author":"Harrison","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0565","doi-asserted-by":"crossref","first-page":"9960","DOI":"10.1021\/acs.jmedchem.7b00907","article-title":"Discovery of Tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of Cholestatic liver diseases and nonalcoholic steatohepatitis (NASH)","volume":"60","author":"Tully","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0570","article-title":"Safety and efficacy of tropifexor in patients with fibrotic nonalcoholic steatohepatitis: 48-week results from Part C of the Phase 2 FLIGT-FXR study","volume":"72","author":"Lucas","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0575","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056159","volume":"12","author":"Amin","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0580","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1038\/s41591-021-01489-1","article-title":"ACC inhibitor alone or co-administered with a DGAT2 inhibitor in patients with non-alcoholic fatty liver disease: two parallel, placebo-controlled, randomized phase 2a trials","volume":"27","author":"Calle","year":"2021","journal-title":"Nat. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0585","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0590","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1016\/j.bmc.2017.06.052","article-title":"Therapeutic peptides: historical perspectives, current development trends, and future directions","volume":"26","author":"Lau","year":"2018","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0595","doi-asserted-by":"crossref","first-page":"170208","DOI":"10.1016\/j.peptides.2019.170208","article-title":"The influence of glucose-dependent Insulinotropic polypeptide (GIP) on human adipose tissue and fat metabolism: implications for obesity, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD)","volume":"125","author":"Thondam","year":"2020","journal-title":"Peptides"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0600","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/dom.12395","article-title":"Restoration of the insulinotropic effect of glucose-dependent insulinotropic polypeptide contributes to the antidiabetic effect of dipeptidyl peptidase-4 inhibitors","volume":"17","author":"Aaboe","year":"2015","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0605","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s00125-008-1195-5","article-title":"Four weeks of near-normalisation of blood glucose improves the insulin response to glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes","volume":"52","author":"Hojberg","year":"2009","journal-title":"Diabetologia"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0610","doi-asserted-by":"crossref","first-page":"101090","DOI":"10.1016\/j.molmet.2020.101090","article-title":"Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease","volume":"46","author":"Baggio","year":"2021","journal-title":"Mol Metab"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0615","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/j.cmet.2019.07.013","article-title":"Glucose-dependent Insulinotropic polypeptide receptor-expressing cells in the hypothalamus regulate food intake","volume":"30","author":"Adriaenssens","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0620","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1038\/s42255-020-0209-6","article-title":"Resolution of NASH and hepatic fibrosis by the GLP-1R and GCGR dual-agonist cotadutide via modulating mitochondrial function and lipogenesis","volume":"2","author":"Boland","year":"2020","journal-title":"Nat. Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0625","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/MED.0000000000000514","article-title":"Gastrointestinal peptides and nonalcoholic fatty liver disease","volume":"27","author":"Tarantino","year":"2020","journal-title":"Curr. Opin. Endocrinol. Diabetes Obes."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0630","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/s41366-019-0386-0","article-title":"Long-acting CCK analogue NN9056 lowers food intake and body weight in obese Gottingen Minipigs","volume":"44","author":"Christoffersen","year":"2020","journal-title":"Int. J. Obes. (Lond)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0635","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.tem.2016.04.002","article-title":"Metabolic actions of the type 1 cholecystokinin receptor: its potential as a therapeutic target","volume":"27","author":"Miller","year":"2016","journal-title":"Trends Endocrinol. Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0640","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.appet.2018.05.131","article-title":"A GLP-1:CCK fusion peptide harnesses the synergistic effects on metabolism of CCK-1 and GLP-1 receptor agonism in mice","volume":"127","author":"Hornigold","year":"2018","journal-title":"Appetite"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0645","first-page":"1","article-title":"Effects of 2 novel PYY(1\u201336) analogues, (P3L31P34)PYY(1\u201336) and PYY(1\u201336)(Lys12PAL), on pancreatic beta-cell function, growth, and survival","volume":"12","author":"Lafferty","year":"2019","journal-title":"Clinical Medicine Insights: Endocrinology and Diabetes"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0650","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmet.2019.01.017","article-title":"A long-acting PYY(3-36) analog mediates robust anorectic efficacy with minimal Emesis in nonhuman primates","volume":"29","author":"Rangwala","year":"2019","journal-title":"Cell Metab."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0655","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1111\/liv.14802","article-title":"Fibroblast growth factor 19: potential modulation of hepatic metabolism for the treatment of non-alcoholic fatty liver disease","volume":"41","author":"Sciarrillo","year":"2021","journal-title":"Liver Int."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0660","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1002\/hep.30590","article-title":"NGM282 improves liver fibrosis and histology in 12 weeks in patients with nonalcoholic steatohepatitis","volume":"71","author":"Harrison","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0665","doi-asserted-by":"crossref","first-page":"597583","DOI":"10.3389\/fendo.2020.597583","article-title":"Pathophysiology of NAFLD and NASH in experimental models: the role of food intake regulating peptides","volume":"11","author":"Korinkova","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0670","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1080\/13813455.2018.1437638","article-title":"Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation","volume":"125","author":"Khaleel","year":"2019","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0675","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.tips.2019.12.005","article-title":"Targeting FGF21 for the treatment of nonalcoholic steatohepatitis","volume":"41","author":"Zarei","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0680","doi-asserted-by":"crossref","first-page":"2705","DOI":"10.1016\/S0140-6736(18)31785-9","article-title":"Pegbelfermin (BMS-986036), a PEGylated fibroblast growth factor 21 analogue, in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 2a trial","volume":"392","author":"Sanyal","year":"2019","journal-title":"Lancet"},{"issue":"23","key":"10.1016\/j.jconrel.2023.09.040_bb0685","first-page":"00310-5","article-title":"Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): a randomized phase 2b study","volume":"S1542-3565","author":"Loomba","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0690","first-page":"814","article-title":"Metreleptin therapy for nonalcoholic steatohepatitis: open-label therapy interventions in two different clinical settings","volume":"2","author":"Akinci","year":"2021","journal-title":"Med (N Y)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0695","doi-asserted-by":"crossref","first-page":"2752","DOI":"10.1038\/s41598-017-02848-0","article-title":"Normalization of adiponectin concentrations by leptin replacement in Ob\/Ob mice is accompanied by reductions in systemic oxidative stress and inflammation","volume":"7","author":"Fruhbeck","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0700","doi-asserted-by":"crossref","first-page":"32584","DOI":"10.1073\/pnas.1922169117","article-title":"Mechanisms by which adiponectin reverses high fat diet-induced insulin resistance in mice","volume":"117","author":"Li","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0705","doi-asserted-by":"crossref","first-page":"5807","DOI":"10.1038\/s41467-020-19668-y","article-title":"AdipoR1\/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis","volume":"11","author":"Xu","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0710","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jcsm.13148","article-title":"AdipoRon enhances healthspan in middle-aged obese mice: striking alleviation of myosteatosis and muscle degenerative markers","volume":"14","author":"Selvais","year":"2022","journal-title":"J. Cachexia. Sarcopenia Muscle"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0715","doi-asserted-by":"crossref","first-page":"114800","DOI":"10.1016\/j.ejmech.2022.114800","article-title":"Discovery of novel AdipoRon analogues as potent anti-inflammatory agents against nonalcoholic steatohepatitis","volume":"244","author":"Dai","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0720","doi-asserted-by":"crossref","first-page":"899731","DOI":"10.3389\/fendo.2022.899731","article-title":"Parathyroid hormone alleviates non-alcoholic liver steatosis via activating the hepatic cAMP\/PKA\/CREB pathway","volume":"13","author":"Feng","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0725","doi-asserted-by":"crossref","first-page":"3865","DOI":"10.2147\/DDDT.S258857","article-title":"Phoenixin 14 inhibits high-fat diet-induced non-alcoholic fatty liver disease in experimental mice","volume":"14","author":"Yang","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0730","doi-asserted-by":"crossref","first-page":"3926","DOI":"10.3892\/etm.2017.4934","article-title":"Humanin analogue, S14G-humanin, has neuroprotective effects against oxygen glucose deprivation\/reoxygenation by reactivating Jak2\/Stat3 signaling through the PI3K\/AKT pathway","volume":"14","author":"Gao","year":"2017","journal-title":"Exp. Ther. Med."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0735","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.bbrc.2020.03.128","article-title":"Humanin attenuates palmitate-induced hepatic lipid accumulation and insulin resistance via AMPK-mediated suppression of the mTOR pathway","volume":"526","author":"Kwon","year":"2020","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0740","first-page":"2573","article-title":"S14G-humanin restored cellular homeostasis disturbed by amyloid-beta protein","volume":"8","author":"Li","year":"2013","journal-title":"Neural Regen. Res."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0745","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/gutjnl-2019-319146","article-title":"Novel strategy for oral peptide delivery in incretin-based diabetes treatment","volume":"69","author":"Xu","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0750","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1021\/acs.molpharmaceut.7b00742","article-title":"Size effect on lipid nanocapsule-mediated GLP-1 secretion from Enteroendocrine L cells","volume":"15","author":"Xu","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0755","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1021\/acs.molpharmaceut.6b00871","article-title":"A mechanistic study on nanoparticle-mediated glucagon-like Peptide-1 (GLP-1) secretion from Enteroendocrine L cells","volume":"13","author":"Beloqui","year":"2016","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0760","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jconrel.2023.03.012","article-title":"Exploiting the biological effect exerted by lipid nanocapsules in non-alcoholic fatty liver disease","volume":"356","author":"Domingues","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0765","doi-asserted-by":"crossref","first-page":"5235","DOI":"10.12998\/wjcc.v8.i21.5235","article-title":"Essential phospholipids for nonalcoholic fatty liver disease associated with metabolic syndrome: a systematic review and network meta-analysis","volume":"8","author":"Dajani","year":"2020","journal-title":"World Journal of Clinical Cases"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0770","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.addr.2021.04.003","article-title":"Lipid based nanocarriers for effective drug delivery and treatment of diabetes associated liver fibrosis","volume":"173","author":"Salunkhe","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0775","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1111\/bph.12837","article-title":"Ursodeoxycholyl lysophosphatidylethanolamide attenuates hepatofibrogenesis by impairment of TGF-beta1\/Smad2\/3 signalling","volume":"171","author":"Pathil","year":"2014","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0780","doi-asserted-by":"crossref","first-page":"6404","DOI":"10.1021\/jf400545w","article-title":"Altered hepatic gene expression profiles associated with improved fatty liver, insulin resistance, and intestinal permeability after hydroxypropyl methylcellulose (HPMC) supplementation in diet-induced obese mice","volume":"61","author":"Kim","year":"2013","journal-title":"J. Agric. Food Chem."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0785","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1096\/fj.12-219477","article-title":"The nonfermentable dietary fiber hydroxypropyl methylcellulose modulates intestinal microbiota","volume":"27","author":"Cox","year":"2013","journal-title":"FASEB J."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0790","doi-asserted-by":"crossref","DOI":"10.3390\/ma12244239","article-title":"HPMC- and PLGA-based nanoparticles for the mucoadhesive delivery of sitagliptin: optimization and in vivo evaluation in rats","volume":"12","author":"Nair","year":"2019","journal-title":"Materials (Basel)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0795","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1211\/jpp.58.2.0007","article-title":"Low molecular weight chitosan inhibits obesity induced by feeding a high-fat diet long-term in mice","volume":"58","author":"Sumiyoshi","year":"2006","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0800","doi-asserted-by":"crossref","DOI":"10.3390\/ph14030215","article-title":"The evaluation of drug delivery nanocarrier development and pharmacological briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): an update","volume":"14","author":"Abou Assi","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0805","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s12951-018-0391-9","article-title":"Chitosan-functionalized lipid-polymer hybrid nanoparticles for oral delivery of silymarin and enhanced lipid-lowering effect in NAFLD","volume":"16","author":"Liang","year":"2018","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0810","doi-asserted-by":"crossref","DOI":"10.3390\/md17110645","article-title":"Chitosan oligosaccharide attenuates nonalcoholic fatty liver disease induced by high fat diet through reducing lipid accumulation, inflammation and oxidative stress in C57BL\/6 Mice","volume":"17","author":"Tao","year":"2019","journal-title":"Mar Drugs"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0815","doi-asserted-by":"crossref","first-page":"271","DOI":"10.15171\/apb.2019.031","article-title":"Omega-3 fatty acid based nanolipid formulation of atorvastatin for treating hyperlipidemia","volume":"9","author":"Sreedhar","year":"2019","journal-title":"Adv Pharm Bull"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0820","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s43094-022-00400-0","article-title":"Pharmaceutical nanotechnology: from the bench to the market","volume":"8","author":"Mazayen","year":"2022","journal-title":"Futur J Pharm Sci"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0825","doi-asserted-by":"crossref","first-page":"6295","DOI":"10.2147\/IJN.S257269","article-title":"The influence of nanoparticle properties on oral bioavailability of drugs","volume":"15","author":"Wang","year":"2020","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0830","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.2217\/nnm.12.87","article-title":"Nanotechnology in therapeutics: a focus on nanoparticles as a drug delivery system","volume":"7","author":"Suwussa Bamrungsap","year":"2012","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0835","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.addr.2016.10.005","article-title":"Oral delivery of peptides: opportunities and issues for translation","volume":"106","author":"Brayden","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0840","doi-asserted-by":"crossref","first-page":"4041415","DOI":"10.1155\/2021\/4041415","article-title":"The emerging role of nanomedicine in the management of nonalcoholic Fatty Liver Disease: a state-of-the-art review","volume":"2021","author":"Moosavian","year":"2021","journal-title":"Bioinorg. Chem. Appl."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0845","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222413424","article-title":"It is high time physicians thought of natural products for alleviating NAFLD. Is there sufficient evidence to use them?","volume":"22","author":"Tarantino","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0850","doi-asserted-by":"crossref","first-page":"5049","DOI":"10.2147\/IJN.S84565","article-title":"Berberine-loaded solid lipid nanoparticles are concentrated in the liver and ameliorate hepatosteatosis in db\/db mice","volume":"10","author":"Xue","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0855","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.2147\/IJN.S51262","article-title":"Characterization, pharmacokinetics, and hypoglycemic effect of berberine loaded solid lipid nanoparticles","volume":"8","author":"Xue","year":"2013","journal-title":"Int. J. Nanomedicine"},{"issue":"6","key":"10.1016\/j.jconrel.2023.09.040_bb0860","doi-asserted-by":"crossref","first-page":"2217","DOI":"10.1002\/ptr.7764","article-title":"Efficacy of curcumin plus piperine co-supplementation in moderate-to-high hepatic steatosis: a double-blind, randomized, placebo-controlled clinical trial","volume":"37","author":"Sharifi","year":"2023","journal-title":"Phytother. Res."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0865","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12951-021-00979-1","article-title":"Improving the ameliorative effects of berberine and curcumin combination via dextran-coated bilosomes on non-alcohol fatty liver disease in mice","volume":"19","author":"Chen","year":"2021","journal-title":"J Nanobiotechnology"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0870","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2217\/nnm-2017-0119","article-title":"Nanoliposomes improves inhibitory effects of naringenin on NAFLD in mice","volume":"12","author":"Cong Chen","year":"2017","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0875","doi-asserted-by":"crossref","first-page":"102310","DOI":"10.1016\/j.nano.2020.102310","article-title":"Formulation and intestinal absorption of naringenin loaded nanostructured lipid carrier and its inhibitory effects on nonalcoholic fatty liver disease","volume":"32","author":"Hu","year":"2021","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0880","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/bph.14938","article-title":"Naringenin attenuates non-alcoholic fatty liver disease by down-regulating the NLRP3\/NF-kappaB pathway in mice","volume":"177","author":"Wang","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0885","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.2217\/nnm.15.87","article-title":"Redox NP as a novel treatment approach for inflammation and fibrosis associated with NASH","volume":"10","author":"Akiko Eguchi","year":"2015","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0890","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23063131","article-title":"A novel sprague-dawley rat model presents improved NASH\/NAFLD symptoms with PEG coated vitexin liposomes","volume":"23","author":"Farooq","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0895","doi-asserted-by":"crossref","first-page":"173264","DOI":"10.1016\/j.ejphar.2020.173264","article-title":"Vitexin ameliorates chronic stress plub high fat diet-induced nonalcoholic fatty liver disease by inhibiting inflammation","volume":"882","author":"Li","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0900","doi-asserted-by":"crossref","first-page":"109683","DOI":"10.1016\/j.biopha.2019.109683","article-title":"Effect of vitexin on alleviating liver inflammation in a dextran sulfate sodium (DSS)-induced colitis model","volume":"121","author":"Duan","year":"2020","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0905","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1208\/s12249-022-02255-3","article-title":"Development, characterization, and investigation of in vivo targeted delivery efficacy of Luteolin-loaded, Eudragit S100-coated mPEG-PLGA nanoparticles","volume":"23","author":"Liu","year":"2022","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0910","doi-asserted-by":"crossref","first-page":"109019","DOI":"10.1016\/j.abb.2021.109019","article-title":"Luteolin alleviates non-alcoholic fatty liver disease in rats via restoration of intestinal mucosal barrier damage and microbiota imbalance involving in gut-liver axis","volume":"711","author":"Liu","year":"2021","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0915","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1016\/j.nano.2016.07.002","article-title":"Fenofibrate nanoliposome: preparation and its inhibitory effects on nonalcoholic fatty liver disease in mice","volume":"12","author":"Cao","year":"2016","journal-title":"Nanomedicine"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0920","doi-asserted-by":"crossref","first-page":"120576","DOI":"10.1016\/j.ijpharm.2021.120576","article-title":"Inositol hexanicotinate self-micelle solid dispersion is an efficient drug delivery system in the mouse model of non-alcoholic fatty liver disease","volume":"602","author":"Zheng","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0925","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1248\/bpb.b20-00432","article-title":"A lipid-based Nanocarrier containing active vitamin D3 ameliorates NASH in mice via direct and intestine-mediated effects on liver inflammation","volume":"43","author":"Yunmei Mu","year":"2020","journal-title":"Biol. Pharma. Bull"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0930","doi-asserted-by":"crossref","first-page":"38925","DOI":"10.1021\/acsami.0c09814","article-title":"Oral GLP1 gene delivery by an antibody-guided nanomaterial to treat type 2 diabetes mellitus","volume":"12","author":"Hasan","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0935","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1039\/C6NR00294C","article-title":"In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy","volume":"8","author":"Araujo","year":"2016","journal-title":"Nanoscale"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0940","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/S2213-8587(19)30192-5","article-title":"Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial","volume":"7","author":"Mosenzon","year":"2019","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0945","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1007\/s13340-019-00423-8","article-title":"The development of oral semaglutide, an oral GLP-1 analog, for the treatment of type 2 diabetes","volume":"11","author":"Rasmussen","year":"2020","journal-title":"Diabetol. Int."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0950","doi-asserted-by":"crossref","first-page":"22521","DOI":"10.1038\/s41598-021-01750-0","article-title":"Development of an orally delivered GLP-1 receptor agonist through peptide engineering and drug delivery to treat chronic disease","volume":"11","author":"Pechenov","year":"2021","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0955","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.addr.2012.11.003","article-title":"Multi-compartmental oral delivery systems for nucleic acid therapy in the gastrointestinal tract","volume":"65","author":"Kriegel","year":"2013","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0960","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.jconrel.2022.01.038","article-title":"Hepatic macrophage targeted siRNA lipid nanoparticles treat non-alcoholic steatohepatitis","volume":"343","author":"Zhou","year":"2022","journal-title":"J. Control. Release"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0965","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1016\/j.xphs.2017.04.042","article-title":"The delivery of small interfering RNA to hepatic stellate cells using a lipid nanoparticle composed of a vitamin A-scaffold lipid-like material","volume":"106","author":"Toriyabe","year":"2017","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0970","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41467-022-35637-z","article-title":"Ligand-tethered lipid nanoparticles for targeted RNA delivery to treat liver fibrosis","volume":"14","author":"Han","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0975","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1038\/s41598-018-20632-6","article-title":"Oral delivery of siRNA lipid nanoparticles: fate in the GI tract","volume":"8","author":"Ball","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0980","article-title":"ITGA5 inhibition in pancreatic stellate cells attenuates desmoplasia and potentiates efficacy of chemotherapy in pancreatic cancer","volume":"5","author":"Praneeth","year":"2019","journal-title":"Science Advances"},{"key":"10.1016\/j.jconrel.2023.09.040_bb0985","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.addr.2018.01.020","article-title":"Integrins in wound healing, fibrosis and tumor stroma: high potential targets for therapeutics and drug delivery","volume":"129","author":"Schnittert","year":"2018","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.jconrel.2023.09.040_bb0990","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19103264","article-title":"Nanoparticle-mediated combination therapy: two-in-one approach for cancer","volume":"19","author":"Gurunathan","year":"2018","journal-title":"Int J Mol Sci"}],"container-title":["Journal of Controlled Release"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168365923006272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T16:51:39Z","timestamp":1759164699000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168365923006272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":198,"alternative-id":["S0168365923006272"],"URL":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.040","relation":{},"ISSN":["0168-3659"],"issn-type":[{"value":"0168-3659","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nonalcoholic fatty liver disease: Current therapies and future perspectives in drug delivery","name":"articletitle","label":"Article Title"},{"value":"Journal of Controlled Release","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jconrel.2023.09.040","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}